Feb 25 (Reuters) - Puma Biotechnology Inc :
* PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
* PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
* PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
* PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
* PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* PUMA BIOTECHNOLOGY AND PIERRE FABRE AMEND NERLYNX® LICENSE AGREEMENT TO INCLUDE GREATER CHINA
* PUMA BIOTECHNOLOGY INC - CO, CANBRIDGE PHARMACEUTICALS TERMINATE LICENSE AGREEMENT IN GREATER CHINA
* PUMA BIOTECHNOLOGY INC - UNDER TERMS, CO WILL RECEIVE AN UPFRONT PAYMENT OF $50 MILLION
* PUMA BIOTECHNOLOGY - UNDER TERMS, CO WILL RECEIVE AN ADDITIONAL REGULATORY, SALES-BASED MILESTONE PAYMENTS THAT COULD ADD UP TO AN ADDITIONAL $240 MILLION
* PUMA BIOTECHNOLOGY INC - IN ADDITION, PUMA WILL RECEIVE SIGNIFICANT DOUBLE-DIGIT TIERED ROYALTIES ON SALES OF NERLYNX IN GREATER CHINA
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)